Company Analysis
Sign in

Galectin Therapeutics Inc. (GALT)

Nasdaq: GALT · Pharmaceutical Preparations · Norcross, GA · filing with the SEC since 2001
Full chart Alerts Compare
Grade6.1
◀ Past 6.7● Present 5.3▶ Future 6.4
6 est.
OverviewBusinessFinancialsGradeForecastSentimentOwnershipPeopleFilingsPatents Chart
The companyfiscal 2025, as filed
Revenuen/a
Net income-$30.8M+34.5%
Earnings per share$-0.48+36.8%
Operating cash flow-$23.9M+42.8%
Cash$17.7M+17.2%
Debtn/a
Shareholders’ equity-$128M-22.1%
Shares, diluted63.9M+2.6%
Return on equityn/a
The recordfrom its filings
Filings in 202656
Newest filingOct 13 · ARS
Annual reportMar 31, 2026
Quarterly reportAug 14, 2026
Next report due10-Q by Nov 14
Insider sales, 12 months$4.8M
Insider buys, 12 months$100,000
Patents granted26
Filer categoryNon-accelerated filer<br>Smaller reporting company
Trailing twelve months to Jun 2026Net income -$27.8MCash from operations -$15.9Mthe four newest filed quarters added
Left: the newest annual report, with the change on the year before. Right: counted from the company's own filings with the SEC.
Revenue and net income by fiscal yearRevenueNet income
16171819202122232425
As filed, in USD. Nothing here is a forecast.

News

Oct 13, 2026 · SEC EDGAR · Form DEFA14A
Extra proxy material
Open the filing on sec.gov
Oct 13, 2026 · SEC EDGAR · Form DEF 14A
Proxy statement
Open the filing on sec.gov
Aug 14, 2026 · SEC EDGAR · Form 8-K
Results released
Open the filing on sec.gov
Aug 14, 2026 · SEC EDGAR · Form 10-Q
Quarterly report
Open the filing on sec.gov
Aug 4, 2026 · SEC EDGAR · Form 8-K
Current report
Open the filing on sec.gov
Aug 4, 2026 · SEC EDGAR · Form 4
Insider trade report
Open the filing on sec.gov
Jul 16, 2026 · SEC EDGAR · Form 4
Insider trade report
Open the filing on sec.gov
An outside story is shown by its headline, its source and its link only. The SI reads the page when you ask it to break one down.
SI Assistanton GALT · research, not advice